Essix Biosciences Increases Stake in Ind-Swift Laboratories via Warrant Conversion
Ind-Swift Laboratories Ltd 路 Others (Uncategorized) 路 12 Oct 2026, 11:05 pm
Essix Biosciences Increases Stake in Ind-Swift Laboratories via Warrant Conversion Essix Biosciences Limited, part of the promoter group of Ind-Swift Laboratories Limited, acquired 14,00,000 equity shares (1.58% voting capital) on 8th Oct'26 through the conversion of preferential convertible warrants. Post-allotment, Essix Biosciences' direct shareholding increased from 37.81% (3,28,82,521 shares) to 38.80% (3,42,82,521 shares), while combined promoter and PAC voting rights rose to 43.84% (4,43,34,278 shares). Ind-Swift's total paid-up voting equity expanded to Rs. 88.36 cr (8,83,61,558 shares of Rs. 10 each), with total diluted capital standing at Rs. 93.96 cr.
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. 路 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. 路 05 Nov 2026
- Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026 路 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants 路 03 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants 路 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... 路 04 Nov 2026
- Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026 路 30 Oct 2026
- Please refer attached pdf 路 30 Oct 2026
